VERV241115C5000
- 0.63
- 0.000.00%
Verve Therapeutics Newsroom
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC Speakers
Jim Cramer on Verve Therapeutics Inc. (VERV): 'I Think It's A Winner'
Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc
Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers
Verve Therapeutics' (VERV) Gene-Editing Therapies Could Be a Game Changer
10 Health Care Stocks Whale Activity In Today's Session
Verve Therapeutics Price Target Cut to $29.00/Share From $30.00 by Canaccord Genuity
HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
Verve Therapeutics, Inc. (NASDAQ:VERV) Just Reported Earnings, And Analysts Cut Their Target Price
RBC Capital Maintains Outperform on Verve Therapeutics, Lowers Price Target to $20
Buy Rating Affirmed for Verve Therapeutics Amidst Clinical Progress and Strong Financials
Express News | Verve Therapeutics Inc : Canaccord Genuity Cuts Target Price to $29 From $30
RBC Capital Remains a Buy on Verve Therapeutics (VERV)
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
Express News | Verve Therapeutics Inc : RBC Cuts Target Price to $20 From $25
Verve Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Verve Therapeutics Inc: Cash Runway Into Late 2026
Express News | Verve Therapeutics Q2 EPS USD -0.59
Express News | Verve Therapeutics Q2 Collaboration Revenue USD 6.692 Million